April 2, 2020 07:20 AM EDTUpdated 10:21 AM

Covid-19 roundup: Amgen joins the race to develop a drug; Doctors, nurses employed by Merck, Lilly, Pfizer can pitch in at the front lines

Natalie Grover

Reporter

Joining forces with Seattle-based Adaptive Technologies, Amgen is looking to develop an antibody-based treatment, echoing efforts from companies including Vir Biotechnology and Regeneron.

Adaptive is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Amgen joins the race to develop a drug; Doctors, nurses employed by Merck, Lilly, Pfizer can pitch in at the front lines

Natalie Grover

Reporter

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Covid-19 roundup: Am­gen joins the race to de­vel­op a drug; Doc­tors, nurs­es em­ployed by Mer­ck, Lil­ly, Pfiz­er can pitch in at the front lines

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Covid-19 roundup: Amgen joins the race to develop a drug; Doctors, nurses employed by Merck, Lilly, Pfizer can pitch in at the front lines

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role